Wednesday, 20 Nov 2019

You are here

MMWR: Increased Opioid Use in Lupus

Opioids are generally not indicated for pain in systemic lupus erythematosus (SLE) and other rheumatic diseases because of limited efficacy and risks for addiction and adverse health effects.

MMWR reports that nearly one third of patients with SLE in an established Michigan cohort used prescription opioids, with approximately two thirds of those using for >1 year. Emergency department use by SLE patients was associated with increased prescription opioid use.

SLE patients have their own morbities and comorbidities. While pain can be a symptom in lupus, the need for narcotics should be rare at best. Short or long-term opioid therapy in these patients should be concerning, if not alarming, and prompt strategies for reducing overall opioid use.

A study compared 462 patients with SLE from the population-based Michigan Lupus Epidemiology and Surveillance (MILES) Cohort with 192 frequency-matched persons without SLE.

They found that nearly one third (31%) of SLE patients were using prescription opioids during the study period (2014–2015), compared with 8% of persons without SLE (p<0.001). Among the SLE patients using opioids, 97 (68%) were using them for >1 year, and 31 (22%) were concomitantly on two or more opioid medications.

Among SLE patients, those using the emergency department (ED) were approximately twice as likely to use prescription opioids (odds ratio [OR] = 2.1; 95% confidence interval [CI] = 1.3–3.6; p = 0.004).

The odds of opioid use among SLE patients were 3 times higher than for nonpatients (OR = 3.4, 95% CI = 1.7–6.6; p <0.001) after accounting for demographic, psychosocial, and clinical factors (Table 3). In analyses of both the total study population and SLE patients only, prescription opioid use was twice as likely among persons who had at least one ED visit in the last 12 months (total population: OR = 2.2, 95% CI 1.4–3.6), SLE patients only: OR = 2.1, 95% CI = 1.3–3.6).

Addressing the widespread and long-term use of opioid therapy in SLE will require strategies aimed at preventing opioid initiation, tapering and discontinuation of opioids among patients who are not achieving treatment goals of reduced pain and increased function, and consideration of nonopioid pain management strategies.


The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Part 1:  The “P” in Prednisone stands for Poison...and Other Pearls

Everyone has life hacks.  Years of experience and doing the same things repetitively allow us to figure out little tricks to make life easier. A rat in a maze, finding itself at a dead end, will back up and search for a clearing. If this rat encounters its neighbor, it will transmit that information so the second rat won’t make the same mistake.

Protective Effects of ASA and Vasodilators in Systemic Sclerosis

A large cohort study suggests that the use of vasodilators and aspirin (ASA) in systemic sclerosis (SSc) may yield favorable  cardiovascular outcomes.

Myositis Patients at High Risk of Opportunistic Infections

Among patients with systemic rheumatic diseases, the highest incidence of opportunistic infections was seen in those with polymyositis/dermatomyositis (PM/DM), Taiwanese researchers found.

Warfarin Superior to Xarelto in Antiphospholipid Syndrome

A 3 year, multicenter, European, study shows that rivaroxaban was inferior to warfarin in preventing thrombosis in patients with antiphospholipid syndrome (APS) according to the Annals of Internal Medicine. Thus despite the inconvenience of warfarin, it remains the best option for patients with APS.

Declining Trends in Antineutrophil Cytoplasmic Autoantibody–Associated Vasculitis Mortality in the USA

Annals of Internal Medicine reports that age-adjusted mortality rates for antineutrophil cytoplasmic autoantibody–associated vasculitides (AAV) have improved over time - with a decline of nearly 2 percent per year in the United States from 1999 to 2017. Nevertheless, long-term outcomes continue to lag behind mortality rates of the general population.